Skip to main content
Top
Published in: Supportive Care in Cancer 3/2024

01-03-2024 | Radiotherapy | Review

Burning mouth in oncology care: a systematic review

Authors: Ana Gabriela Costa Normando, Alan Roger Santos-Silva, Joel B. Epstein

Published in: Supportive Care in Cancer | Issue 3/2024

Login to get access

Abstract

Burning mouth, also referred to as oral dysesthesia, is an underreported condition among cancer patients that may represent an early symptom of cancer or an adverse effect of treatment. This review sought to characterize this symptom in oncology care where burning symptoms may occur. A systematic review of the literature was performed based on the PRISMA statement, and the protocol was registered at PROSPERO database. A structured search was done using eight databases. The process of study selection was conducted in two distinct phases. The JBI Critical Appraisal Tools were utilized to evaluate the risk of bias in the studies included. Of the total number of studies assessed, sixteen met the eligibility criteria. Of these studies included, 7 were case reports, 7 cross-sectional studies, and 2 non-randomized clinical trials. Most studies presented low risk of bias (n = 9), while the remaining studies were evaluated and scored as moderate (n = 5) or high (n = 2) risk of bias. Burning mouth was reported as a first symptom of cancer in three studies, and as an adverse event of radiotherapy (n = 2), chemoradiotherapy (n = 2), and chemotherapy (n = 9). Burning mouth was a first symptom in 0.62% of oral squamous cell carcinoma (OSCC), and 3.3% of patients with pain as chief complaint. Oral dysesthesia prevalence was 13.6% in patients experiencing chemotherapy-induced oral adverse events. The symptom of burning mouth should be examined in oncology care, as it may be underreported and therefore undertreated. New therapies may be related to a higher risk of oral burning and studies assessing approach to management are needed. Current management borrows from the current management of burning mouth in the non-cancer setting.
Appendix
Available only for authorised users
Literature
8.
go back to reference National Cancer Institute NIH, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 2017 National Cancer Institute NIH, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 2017
15.
go back to reference Moola, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R et al (2020) Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis, JBI Moola, Munn Z, Tufanaru C, Aromataris E, Sears K, Sfetcu R et al (2020) Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis, JBI
20.
go back to reference el Mobadder M, Farhat F, el Mobadder W, Nammour S (2019) Photobiomodulation Therapy in the Treatment of Oral Mucositis, Dysphagia, Oral Dryness, Taste Alteration, and Burning Mouth Sensation Due to Cancer Therapy: A Case Series. Int J Environ Res Public Health 16. https://doi.org/10.3390/IJERPH16224505 el Mobadder M, Farhat F, el Mobadder W, Nammour S (2019) Photobiomodulation Therapy in the Treatment of Oral Mucositis, Dysphagia, Oral Dryness, Taste Alteration, and Burning Mouth Sensation Due to Cancer Therapy: A Case Series. Int J Environ Res Public Health 16. https://​doi.​org/​10.​3390/​IJERPH16224505
22.
go back to reference Okamoto I, Okada T, Tokashiki K, Tsukahara K (2022) Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. Cancers (Basel) 14. https://doi.org/10.3390/CANCERS14184413. Okamoto I, Okada T, Tokashiki K, Tsukahara K (2022) Quality-of-Life Evaluation of Patients with Unresectable Locally Advanced or Locally Recurrent Head and Neck Carcinoma Treated with Head and Neck Photoimmunotherapy. Cancers (Basel) 14. https://​doi.​org/​10.​3390/​CANCERS14184413.
24.
go back to reference Papadopoulou E, Vardas E, Tziveleka S, Georgaki M, Kouri M, Katoumas K, et al (2022) Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib-Report of Three Cases. Dent J (Basel) 10. https://doi.org/10.3390/DJ10120232 Papadopoulou E, Vardas E, Tziveleka S, Georgaki M, Kouri M, Katoumas K, et al (2022) Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib-Report of Three Cases. Dent J (Basel) 10. https://​doi.​org/​10.​3390/​DJ10120232
41.
go back to reference López-D’alessandro E, Escovich L (2011) Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 16. https://doi.org/10.4317/MEDORAL.16942 López-D’alessandro E, Escovich L (2011) Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 16. https://​doi.​org/​10.​4317/​MEDORAL.​16942
42.
go back to reference Xu Y, Wen N, Sonis ST, Villa A (2021) Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women’s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer 127:1796–1804. https://doi.org/10.1002/cncr.33436CrossRefPubMed Xu Y, Wen N, Sonis ST, Villa A (2021) Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women’s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer 127:1796–1804. https://​doi.​org/​10.​1002/​cncr.​33436CrossRefPubMed
52.
go back to reference Bogetto F, BonattoRevello R, Ferro G, Maina G, Ravizza L (1999) Psychopharmacological treatment of Burning Mouth Syndrome (BMS). A study on a sample of 121 patients. Minerva Psichiatr 40:1–10 Bogetto F, BonattoRevello R, Ferro G, Maina G, Ravizza L (1999) Psychopharmacological treatment of Burning Mouth Syndrome (BMS). A study on a sample of 121 patients. Minerva Psichiatr 40:1–10
55.
go back to reference Nakamura M, Yoshimi A, Mouri A, Tokura T, Kimura H, Kishi S et al (2022) Duloxetine attenuates pain in association with downregulation of platelet serotonin transporter in patients with burning mouth syndrome and atypical odontalgia. Hum Psychopharmacol 37. https://doi.org/10.1002/HUP.2818 Nakamura M, Yoshimi A, Mouri A, Tokura T, Kimura H, Kishi S et al (2022) Duloxetine attenuates pain in association with downregulation of platelet serotonin transporter in patients with burning mouth syndrome and atypical odontalgia. Hum Psychopharmacol 37. https://​doi.​org/​10.​1002/​HUP.​2818
Metadata
Title
Burning mouth in oncology care: a systematic review
Authors
Ana Gabriela Costa Normando
Alan Roger Santos-Silva
Joel B. Epstein
Publication date
01-03-2024
Publisher
Springer Berlin Heidelberg
Keyword
Radiotherapy
Published in
Supportive Care in Cancer / Issue 3/2024
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-024-08383-9

Other articles of this Issue 3/2024

Supportive Care in Cancer 3/2024 Go to the issue